Develops human vaccines against infectious diseases. Creates immunotherapies for various cancers. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Average growth of 59% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
This company is not turning a profit, so the market is pricing its sales instead: 1.4× for every dollar of annual revenue.
Against companies in its own sector, it looks cheaper than 4% of them.
Analysts' average target sits 21,498% above today's price.
Executives buying with their own money is usually read as confidence in the company’s future.
An investor who bought at the very peak is down 100% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Sales run at $2.5M a year. A small number, but proof the product has real buyers.
Over the last 12 months, company executives reported 28 buys and 0 sells. Management buying with its own money is usually read as a good sign.
A loss of $21.5M against $2.5M in annual sales. And on top of that, sales fell from the year before.
The stock sits at $0.46. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
This stock swings about 3.7 times as much as the market average. Big rallies — and big drops — can both happen fast.
On our five-subject report card, GOVX sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: GOVX is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (4/100) says the stock isn’t cheap.
Not covered, because the filings we hold do not carry it: the revenue breakdown.